{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["dry eye disease", "immunomodulatory therapy", "inflammation", "signaling pathways", "traditional Chinese medicine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35111787", "DateRevised": {"Year": "2022", "Month": "02", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "01", "Day": "17"}], "Language": ["eng"], "ELocationID": ["815075", "10.3389/fmed.2021.815075"], "Journal": {"ISSN": "2296-858X", "JournalIssue": {"Volume": "8", "PubDate": {"Year": "2021"}}, "Title": "Frontiers in medicine", "ISOAbbreviation": "Front Med (Lausanne)"}, "ArticleTitle": "Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine.", "Pagination": {"StartPage": "815075", "MedlinePgn": "815075"}, "Abstract": {"AbstractText": ["Dry eye is currently one of the most common ocular surface disease. It can lead to ocular discomfort and even cause visual impairment, which greatly affects the work and quality of life of patients. With the increasing incidence of dry eye disease (DED) in recent years, the disease is receiving more and more attention, and has become one of the hot research fields in ophthalmology research. Recently, with the in-depth research on the etiology, pathogenesis and treatment of DED, it has been shown that defects in immune regulation is one of the main pathological mechanisms of DED. Since the non-specific and specific immune response of the ocular surface are jointly regulated, a variety of immune cells and inflammatory factors are involved in the development of DED. The conventional treatment of DED is the application of artificial tears for lubricating the ocular surface. However, for moderate-to-severe DED, treatment with anti-inflammatory drugs is necessary. In this review, the immunomodulatory mechanisms of DED and the latest research progress of its related treatments including Chinese medicine will be discussed."], "CopyrightInformation": "Copyright \u00a9 2022 Ling, Chan, Tsang, Gao, Leung, Lam, Hu and Wong."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Ling", "ForeName": "Jiawei", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Chan", "ForeName": "Ben Chung-Lap", "Initials": "BC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China."}], "LastName": "Tsang", "ForeName": "Miranda Sin-Man", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China."}], "LastName": "Gao", "ForeName": "Xun", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Leung", "ForeName": "Ping Chung", "Initials": "PC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine and State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, Macau SAR, China."}], "LastName": "Lam", "ForeName": "Christopher Wai-Kei", "Initials": "CW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China."}], "LastName": "Hu", "ForeName": "Jiang-Miao", "Initials": "JM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China."}, {"Identifier": [], "Affiliation": "Li Dak Sum Yip Yio Chin R & D Centre for Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Wong", "ForeName": "Chun Kwok", "Initials": "CK"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Med (Lausanne)", "NlmUniqueID": "101648047", "ISSNLinking": "2296-858X"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Galor A, Feuer W, Lee DJ, Florez H, Carter D, Pouyeh B, et al. . Prevalence and risk factors of dry eye syndrome in a United States veterans affairs population. Am J Ophthalmol. (2011) 152:377\u201384 e2. 10.1016/j.ajo.2011.02.026", "ArticleIdList": ["10.1016/j.ajo.2011.02.026", "PMC4113967", "21684522"]}, {"Citation": "Le Q, Ge L, Li M, Wu L, Xu J, Hong J, et al. . Comparison on the vision-related quality of life between outpatients and general population with dry eye syndrome. Acta Ophthalmol. (2014) 92:e124\u201332. 10.1111/aos.12204", "ArticleIdList": ["10.1111/aos.12204", "23901943"]}, {"Citation": "Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. . TFOS DEWS II Epidemiology Report. Ocul Surf. (2017) 15:334\u201365. 10.1016/j.jtos.2017.05.003", "ArticleIdList": ["10.1016/j.jtos.2017.05.003", "28736337"]}, {"Citation": "Gomes JAP, Santo RM. The impact of dry eye disease treatment on patient satisfaction and quality of life: A review. Ocul Surf. (2019) 17:9\u201319. 10.1016/j.jtos.2018.11.003", "ArticleIdList": ["10.1016/j.jtos.2018.11.003", "30419303"]}, {"Citation": "Hantera MM. Trends in dry eye disease management worldwide. Clin Ophthalmol. (2021) 15:165\u201373. 10.2147/OPTH.S281666", "ArticleIdList": ["10.2147/OPTH.S281666", "PMC7814230", "33488065"]}, {"Citation": "Pflugfelder SC, Stern ME. The cornea in keratoconjunctivitis sicca. Exp Eye Res. (2020) 201:108295. 10.1016/j.exer.2020.108295", "ArticleIdList": ["10.1016/j.exer.2020.108295", "PMC7736263", "33038387"]}, {"Citation": "Mochizuki M, Sugita S, Kamoi K. Immunological homeostasis of the eye. Prog Retin Eye Res. (2013) 33:10\u201327. 10.1016/j.preteyeres.2012.10.002", "ArticleIdList": ["10.1016/j.preteyeres.2012.10.002", "23108335"]}, {"Citation": "Stern ME, Schaumburg CS, Siemasko KF, Gao J, Wheeler LA, Grupe DA, et al. . Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease. Invest Ophthalmol Vis Sci. (2012) 53:2062\u201375. 10.1167/iovs.11-9299", "ArticleIdList": ["10.1167/iovs.11-9299", "PMC6713471", "22395876"]}, {"Citation": "Guzman M, Keitelman I, Sabbione F, Trevani AS, Giordano MN, Galletti JG. Mucosal tolerance disruption favors disease progression in an extraorbital lacrimal gland excision model of murine dry eye. Exp Eye Res. (2016) 151:19\u201322. 10.1016/j.exer.2016.07.004", "ArticleIdList": ["10.1016/j.exer.2016.07.004", "27443502"]}, {"Citation": "Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. (2017) 124:S4\u2013S13. 10.1016/j.ophtha.2017.07.010", "ArticleIdList": ["10.1016/j.ophtha.2017.07.010", "PMC5657523", "29055361"]}, {"Citation": "Barbosa FL, Xiao Y, Bian F, Coursey TG, Ko BY, Clevers H, et al. . Goblet cells contribute to ocular surface immune tolerance-implications for dry eye disease. Int J Mol Sci. (2017) 18. 10.3390/ijms18050978", "ArticleIdList": ["10.3390/ijms18050978", "PMC5454891", "28475124"]}, {"Citation": "Bertoni A, Alabiso O, Galetto AS, Baldanzi G. Integrins in T cell physiology. Int J Mol Sci. (2018) 19. 10.3390/ijms19020485", "ArticleIdList": ["10.3390/ijms19020485", "PMC5855707", "29415483"]}, {"Citation": "Yamaguchi T. Inflammatory response in dry eye. Invest Ophthalmol Vis Sci. (2018) 59:DES192\u2013DES9. 10.1167/iovs.17-23651", "ArticleIdList": ["10.1167/iovs.17-23651", "30481826"]}, {"Citation": "Zhang X, Volpe EA, Gandhi NB, Schaumburg CS, Siemasko KF, Pangelinan SB, et al. . NK cells promote Th-17 mediated corneal barrier disruption in dry eye. PLoS ONE. (2012) 7:e36822. 10.1371/journal.pone.0036822", "ArticleIdList": ["10.1371/journal.pone.0036822", "PMC3348128", "22590618"]}, {"Citation": "Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. (2012) 130:90\u2013100. 10.1001/archophthalmol.2011.364", "ArticleIdList": ["10.1001/archophthalmol.2011.364", "PMC3677724", "22232476"]}, {"Citation": "Strauss-Albee DM, Horowitz A, Parham P, Blish CA. Coordinated regulation of NK receptor expression in the maturing human immune system. J Immunol. (2014) 193:4871\u20139. 10.4049/jimmunol.1401821", "ArticleIdList": ["10.4049/jimmunol.1401821", "PMC4225175", "25288567"]}, {"Citation": "Hu D, Tjon EC, Andersson KM, Molica GM, Pham MC, Healy B, et al. . Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells. Proc Natl Acad Sci U S A. (2020) 117:30639\u201348. 10.1073/pnas.2007935117", "ArticleIdList": ["10.1073/pnas.2007935117", "PMC7720234", "33203678"]}, {"Citation": "Bian F, Pelegrino FS, Henriksson JT, Pflugfelder SC, Volpe EA, Li DQ, et al. . Differential effects of dexamethasone and doxycycline on inflammation and mmp production in murine alkali-burned corneas associated with dry eye. Ocul Surf. (2016) 14:242\u201354. 10.1016/j.jtos.2015.11.006", "ArticleIdList": ["10.1016/j.jtos.2015.11.006", "PMC4842328", "26772899"]}, {"Citation": "Manoussakis MN, Boiu S, Korkolopoulou P, Kapsogeorgou EK, Kavantzas N, Ziakas P, et al. . Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum. (2007) 56:3977\u201388. 10.1002/art.23073", "ArticleIdList": ["10.1002/art.23073", "18050195"]}, {"Citation": "Sisto M, Lisi S, Ingravallo G, Lofrumento DD, D'Amore M, Ribatti D. Neovascularization is prominent in the chronic inflammatory lesions of Sjogren's syndrome. Int J Exp Pathol. (2014) 95:131\u20137. 10.1111/iep.12061", "ArticleIdList": ["10.1111/iep.12061", "PMC3960040", "24772480"]}, {"Citation": "You IC, Coursey TG, Bian F, Barbosa FL, de Paiva CS, Pflugfelder SC. Macrophage Phenotype in the Ocular Surface of Experimental Murine Dry Eye Disease. Arch Immunol Ther Exp (Warsz). (2015) 63:299\u2013304. 10.1007/s00005-015-0335-0", "ArticleIdList": ["10.1007/s00005-015-0335-0", "PMC4523394", "25772203"]}, {"Citation": "Chen Y, Chauhan SK, Saban DR, Sadrai Z, Okanobo A, Dana R. Interferon-gamma-secreting NK cells promote induction of dry eye disease. J Leukoc Biol. (2011) 89:965\u201372. 10.1189/jlb.1110611", "ArticleIdList": ["10.1189/jlb.1110611", "PMC3100760", "21402771"]}, {"Citation": "De Paiva CS, Raince JK, McClellan AJ, Shanmugam KP, Pangelinan SB, Volpe EA, et al. . Homeostatic control of conjunctival mucosal goblet cells by NKT-derived IL-13. Mucosal Immunol. (2011) 4:397\u2013408. 10.1038/mi.2010.82", "ArticleIdList": ["10.1038/mi.2010.82", "PMC3577073", "21178983"]}, {"Citation": "Lee MH, Choi JW, Jang WR, Kim JM, Kim JH. Activation of eosinophils is more closely linked with interleukin-5 and nitric oxide production than tumor necrosis factor-alpha and immunoglobulin E levels. Acta Haematol. (2013) 130:238\u201341. 10.1159/000350474", "ArticleIdList": ["10.1159/000350474", "23860462"]}, {"Citation": "Galletti JG, Guzman M, Giordano MN. Mucosal immune tolerance at the ocular surface in health and disease. Immunology. (2017) 150:397\u2013407. 10.1111/imm.12716", "ArticleIdList": ["10.1111/imm.12716", "PMC5343370", "28108991"]}, {"Citation": "Alam J, de Paiva CS, Pflugfelder SC. Desiccation induced conjunctival monocyte recruitment and activation - implications for keratoconjunctivitis. Front Immunol. (2021) 12:701415. 10.3389/fimmu.2021.701415", "ArticleIdList": ["10.3389/fimmu.2021.701415", "PMC8297564", "34305940"]}, {"Citation": "Yoon KC, Park CS, You IC, Choi HJ, Lee KH, Im SK, et al. . Expression of CXCL9,\u221210,\u221211, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci. (2010) 51:643\u201350. 10.1167/iovs.09-3425", "ArticleIdList": ["10.1167/iovs.09-3425", "PMC3258976", "19850844"]}, {"Citation": "Pflugfelder SC. Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture. Am J Ophthalmol. (2011) 152:900\u20139 e1. 10.1016/j.ajo.2011.08.023", "ArticleIdList": ["10.1016/j.ajo.2011.08.023", "PMC3223272", "22019306"]}, {"Citation": "Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. (2007) 8:345\u201350. 10.1038/ni0407-345", "ArticleIdList": ["10.1038/ni0407-345", "17375096"]}, {"Citation": "De Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher JD. 3rd, Fang B, Zheng X, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. (2009) 2:243\u201353. 10.1038/mi.2009.5", "ArticleIdList": ["10.1038/mi.2009.5", "PMC3594767", "19242409"]}, {"Citation": "Barabino S, Montaldo E, Solignani F, Valente C, Mingari MC, Rolando M. Immune response in the conjunctival epithelium of patients with dry eye. Exp Eye Res. (2010) 91:524\u20139. 10.1016/j.exer.2010.07.008", "ArticleIdList": ["10.1016/j.exer.2010.07.008", "20654615"]}, {"Citation": "McClellan AJ, Volpe EA, Zhang X, Darlington GJ, Li DQ, Pflugfelder SC, et al. . Ocular surface disease and dacryoadenitis in aging C57BL/6 mice. Am J Pathol. (2014) 184:631\u201343. 10.1016/j.ajpath.2013.11.019", "ArticleIdList": ["10.1016/j.ajpath.2013.11.019", "PMC3936306", "24389165"]}, {"Citation": "Subbarayal B, Chauhan SK, Di Zazzo A, Dana R. IL-17 augments B cell activation in ocular surface autoimmunity. J Immunol. (2016) 197:3464\u201370. 10.4049/jimmunol.1502641", "ArticleIdList": ["10.4049/jimmunol.1502641", "PMC5101134", "27655846"]}, {"Citation": "Tsubota K, Pflugfelder SC, Liu Z, Baudouin C, Kim HM, Messmer EM, et al. . Defining dry eye from a clinical perspective. Int J Mol Sci. (2020) 21:9271. 10.3390/ijms21239271", "ArticleIdList": ["10.3390/ijms21239271", "PMC7730816", "33291796"]}, {"Citation": "Yu L, Yu C, Dong H, Mu Y, Zhang R, Zhang Q, et al. . Recent Developments About the Pathogenesis of Dry Eye Disease: Based on Immune Inflammatory Mechanisms. Front Pharmacol. (2021) 12:732887. 10.3389/fphar.2021.732887", "ArticleIdList": ["10.3389/fphar.2021.732887", "PMC8375318", "34421626"]}, {"Citation": "Sekhon AS, He B, Iovieno A, Yeung SN. Pathophysiology of corneal endothelial cell loss in dry eye disease and other inflammatory ocular disorders. Ocul Immunol Inflamm. (2021) 1\u201311. 10.1080/09273948.2021.1980808", "ArticleIdList": ["10.1080/09273948.2021.1980808", "34678119"]}, {"Citation": "Ponzini E, Scotti L, Grandori R, Tavazzi S, Zambon A. Lactoferrin concentration in human tears and ocular diseases: a meta-analysis. Invest Ophthalmol Vis Sci. (2020) 61:9. 10.1167/iovs.61.12.9", "ArticleIdList": ["10.1167/iovs.61.12.9", "PMC7552940", "33035290"]}, {"Citation": "Zhang Y, Lu C, Zhang J. Lactoferrin and its detection methods: a review. Nutrients. (2021) 13:2492. 10.3390/nu13082492", "ArticleIdList": ["10.3390/nu13082492", "PMC8398339", "34444652"]}, {"Citation": "van Setten GB. Osmokinetics: A new dynamic concept in dry eye disease. J Fr Ophtalmol. (2019) 42:221\u20135. 10.1016/j.jfo.2018.11.001", "ArticleIdList": ["10.1016/j.jfo.2018.11.001", "30851972"]}, {"Citation": "Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci. (2006) 47:4309\u201315. 10.1167/iovs.05-1504", "ArticleIdList": ["10.1167/iovs.05-1504", "17003420"]}, {"Citation": "Suzuki M, Massingale ML, Ye F, Godbold J, Elfassy T, Vallabhajosyula M, et al. . Tear osmolarity as a biomarker for dry eye disease severity. Invest Ophthalmol Vis Sci. (2010) 51:4557\u201361. 10.1167/iovs.09-4596", "ArticleIdList": ["10.1167/iovs.09-4596", "20393114"]}, {"Citation": "VanDerMeid KR, Su SP, Ward KW, Zhang JZ. Correlation of tear inflammatory cytokines and matrix metalloproteinases with four dry eye diagnostic tests. Invest Ophthalmol Vis Sci. (2012) 53:1512\u20138. 10.1167/iovs.11-7627", "ArticleIdList": ["10.1167/iovs.11-7627", "22323462"]}, {"Citation": "Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. (2004) 45:4293\u2013301. 10.1167/iovs.03-1145", "ArticleIdList": ["10.1167/iovs.03-1145", "15557435"]}, {"Citation": "Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC, et al. . and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. (2006) 82:588\u201396. 10.1016/j.exer.2005.08.019", "ArticleIdList": ["10.1016/j.exer.2005.08.019", "PMC2198933", "16202406"]}, {"Citation": "Shimizu T, Nakamura H, Kawakami A. Role of the innate immunity signaling pathway in the pathogenesis of sjogren's syndrome. Int J Mol Sci. (2021) 22:3090. 10.3390/ijms22063090", "ArticleIdList": ["10.3390/ijms22063090", "PMC8002742", "33803026"]}, {"Citation": "Simmons KT, Xiao Y, Pflugfelder SC, de Paiva CS. Inflammatory response to lipopolysaccharide on the ocular surface in a murine dry eye model. Invest Ophthalmol Vis Sci. (2016) 57:2443\u201351. 10.1167/iovs.15-18396", "ArticleIdList": ["10.1167/iovs.15-18396", "PMC4857831", "27136463"]}, {"Citation": "Karin N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector t cells, and beyond. Front Immunol. (2020) 11:976. 10.3389/fimmu.2020.00976", "ArticleIdList": ["10.3389/fimmu.2020.00976", "PMC7274023", "32547545"]}, {"Citation": "Perez VL, Stern ME, Pflugfelder SC. Inflammatory basis for dry eye disease flares. Exp Eye Res. (2020) 201:108294. 10.1016/j.exer.2020.108294", "ArticleIdList": ["10.1016/j.exer.2020.108294", "PMC7736538", "33039458"]}, {"Citation": "Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. (2019) 11:2515841419870366. 10.1177/2515841419870366", "ArticleIdList": ["10.1177/2515841419870366", "PMC6710705", "31489402"]}, {"Citation": "An S, Raju I, Surenkhuu B, Kwon JE, Gulati S, Karaman M, et al. . Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies. Ocul Surf. (2019) 17:589\u2013614. 10.1016/j.jtos.2019.03.010", "ArticleIdList": ["10.1016/j.jtos.2019.03.010", "PMC6721977", "30965123"]}, {"Citation": "Galletti JG, de Paiva CS. The ocular surface immune system through the eyes of aging. Ocul Surf. (2021) 20:139\u201362. 10.1016/j.jtos.2021.02.007", "ArticleIdList": ["10.1016/j.jtos.2021.02.007", "PMC8113112", "33621658"]}, {"Citation": "Ho TC, Yeh SI, Chen SL, Tsao YP. Integrin alphav and vitronectin prime macrophage-related inflammation and contribute the development of dry eye disease. Int J Mol Sci. (2021) 22:8410. 10.3390/ijms22168410", "ArticleIdList": ["10.3390/ijms22168410", "PMC8395123", "34445121"]}, {"Citation": "Steven P, Schwab S, Kiesewetter A, Saban DR, Stern ME, Gehlsen U. Disease-specific expression of conjunctiva associated lymphoid tissue (CALT) in mouse models of dry eye disease and ocular allergy. Int J Mol Sci. (2020) 21:7514. 10.3390/ijms21207514", "ArticleIdList": ["10.3390/ijms21207514", "PMC7589149", "33053795"]}, {"Citation": "Willcox MDP, Argueso P, Georgiev GA, Holopainen JM, Laurie GW, Millar TJ, et al. . TFOS DEWS II tear film report. Ocul Surf. (2017) 15:366\u2013403. 10.1016/j.jtos.2017.03.006", "ArticleIdList": ["10.1016/j.jtos.2017.03.006", "PMC6035753", "28736338"]}, {"Citation": "Pflugfelder SC, Corrales RM, de Paiva CS. T helper cytokines in dry eye disease. Exp Eye Res. (2013) 117:118\u201325. 10.1016/j.exer.2013.08.013", "ArticleIdList": ["10.1016/j.exer.2013.08.013", "PMC3855838", "24012834"]}, {"Citation": "Chen Y, Dana R. Autoimmunity in dry eye disease - An updated review of evidence on effector and memory Th17 cells in disease pathogenicity. Autoimmun Rev. (2021) 102933. 10.1016/j.autrev.2021.102933", "ArticleIdList": ["10.1016/j.autrev.2021.102933", "PMC8530974", "34509656"]}, {"Citation": "Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. . TFOS DEWS II pathophysiology report. Ocul Surf. (2017) 15:438\u2013510. 10.1016/j.jtos.2017.05.011", "ArticleIdList": ["10.1016/j.jtos.2017.05.011", "28736340"]}, {"Citation": "Ushio A, Arakaki R, Eguchi H, Hotta F, Yamada A, Kudo Y, et al. . Pathological analysis of ocular lesions in a murine model of sjogren's syndrome. Int J Mol Sci. (2017) 18:1209. 10.3390/ijms18061209", "ArticleIdList": ["10.3390/ijms18061209", "PMC5486032", "28587293"]}, {"Citation": "Teijeira A, Hunter MC, Russo E, Proulx ST, Frei T, Debes GF, et al. . T cell migration from inflamed skin to draining lymph nodes requires intralymphatic crawling supported by ICAM-1/LFA-1 interactions. Cell Rep. (2017) 18:857\u201365. 10.1016/j.celrep.2016.12.078", "ArticleIdList": ["10.1016/j.celrep.2016.12.078", "28122237"]}, {"Citation": "Chivasso C, Sarrand J, Perret J, Delporte C, Soyfoo MS. The involvement of innate and adaptive immunity in the initiation and perpetuation of sjogren's syndrome. Int J Mol Sci. (2021) 22:658. 10.3390/ijms22020658", "ArticleIdList": ["10.3390/ijms22020658", "PMC7826728", "33440862"]}, {"Citation": "Reyes JL, Vannan DT, Eksteen B, Avelar IJ, Rodriguez T, Gonzalez MI, et al. . Innate and adaptive cell populations driving inflammation in dry eye disease. Mediators Inflamm. (2018) 2018:2532314. 10.1155/2018/2532314", "ArticleIdList": ["10.1155/2018/2532314", "PMC6109495", "30158831"]}, {"Citation": "Muller WA. How endothelial cells regulate transmigration of leukocytes in the inflammatory response. Am J Pathol. (2014) 184:886\u201396. 10.1016/j.ajpath.2013.12.033", "ArticleIdList": ["10.1016/j.ajpath.2013.12.033", "PMC3969991", "24655376"]}, {"Citation": "Rouzaut A, Garasa S, Teijeira A, Gonzalez I, Martinez-Forero I, Suarez N, et al. . Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-alpha. Eur J Immunol. (2010) 40:3054\u201363. 10.1002/eji.201040523", "ArticleIdList": ["10.1002/eji.201040523", "21061437"]}, {"Citation": "Jackson DG. Leucocyte Trafficking via the Lymphatic Vasculature- Mechanisms and Consequences. Front Immunol. (2019) 10:471. 10.3389/fimmu.2019.00471", "ArticleIdList": ["10.3389/fimmu.2019.00471", "PMC6426755", "30923528"]}, {"Citation": "Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther. (2020) 36:137\u201346. 10.1089/jop.2019.0060", "ArticleIdList": ["10.1089/jop.2019.0060", "PMC7175622", "32175799"]}, {"Citation": "El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, Dana R. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci. (2009) 50:3802\u20137. 10.1167/iovs.08-2417", "ArticleIdList": ["10.1167/iovs.08-2417", "PMC2921683", "19339740"]}, {"Citation": "Rios-Rios WJ, Sosa-Luis SA, Torres-Aguilar H. T cells subsets in the immunopathology and treatment of sjogren's syndrome. Biomolecules. (2020) 10:1539. 10.3390/biom10111539", "ArticleIdList": ["10.3390/biom10111539", "PMC7698113", "33187265"]}, {"Citation": "Zhang X, De Paiva CS, Su Z, Volpe EA, Li DQ, Pflugfelder SC. Topical interferon-gamma neutralization prevents conjunctival goblet cell loss in experimental murine dry eye. Exp Eye Res. (2014) 118:117\u201324. 10.1016/j.exer.2013.11.011", "ArticleIdList": ["10.1016/j.exer.2013.11.011", "PMC3901360", "24315969"]}, {"Citation": "Alam J, de Paiva CS, Pflugfelder SC. Immune - Goblet cell interaction in the conjunctiva. Ocul Surf. (2020) 18:326\u201334. 10.1016/j.jtos.2019.12.006", "ArticleIdList": ["10.1016/j.jtos.2019.12.006", "PMC7125021", "31953222"]}, {"Citation": "Chauhan SK, Dana R. Role of Th17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol. (2009) 2:375\u20136. 10.1038/mi.2009.21", "ArticleIdList": ["10.1038/mi.2009.21", "PMC2719854", "19532120"]}, {"Citation": "Zheng X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest Ophthalmol Vis Sci. (2010) 51:3083\u201391. 10.1167/iovs.09-3838", "ArticleIdList": ["10.1167/iovs.09-3838", "PMC2891467", "20130281"]}, {"Citation": "Rasool M, Malik A, Abdul Basit Ashraf M, Arooj M, Kiran A, Waquar S, et al. . Role of diagnostic factors associated with antioxidative status and expression of matrix metalloproteinases (MMPs) in patients with cancer therapy induced ocular disorders. Saudi J Biol Sci. (2018) 25:1724\u20138. 10.1016/j.sjbs.2018.08.009", "ArticleIdList": ["10.1016/j.sjbs.2018.08.009", "PMC6303172", "30591791"]}, {"Citation": "Perez VL, Barsam A, Duffort S, Urbieta M, Barreras H, Lightbourn C, et al. . Novel scoring criteria for the evaluation of ocular graft-versus-host disease in a preclinical allogeneic hematopoietic stem cell transplantation animal model. Biol Blood Marrow Transplant. (2016) 22:1765\u201372. 10.1016/j.bbmt.2016.07.012", "ArticleIdList": ["10.1016/j.bbmt.2016.07.012", "PMC5580988", "27492793"]}, {"Citation": "Mastropasqua R, Agnifili L, Fasanella V, Nubile M, Gnama AA, Falconio G, et al. . The conjunctiva-associated lymphoid tissue in chronic ocular surface diseases. Microsc Microanal. (2017) 23:697\u2013707. 10.1017/S1431927617000538", "ArticleIdList": ["10.1017/S1431927617000538", "28480834"]}, {"Citation": "Singh M, Tyagi SC. Hyperhomocysteinemia and Age-related Macular Degeneration: Role of Inflammatory Mediators and Pyroptosis; A Proposal. Med Hypotheses. (2017) 105:17\u201321. 10.1016/j.mehy.2017.06.012", "ArticleIdList": ["10.1016/j.mehy.2017.06.012", "28735646"]}, {"Citation": "Vakrakou AG, Boiu S, Ziakas PD, Xingi E, Boleti H, Manoussakis MN. Systemic activation of NLRP3 inflammasome in patients with severe primary Sjogren's syndrome fueled by inflammagenic DNA accumulations. J Autoimmun. (2018) 91:23\u201333. 10.1016/j.jaut.2018.02.010", "ArticleIdList": ["10.1016/j.jaut.2018.02.010", "29551295"]}, {"Citation": "Zhang J, Dai Y, Yang Y, Xu J. Calcitriol alleviates hyperosmotic stress-induced corneal epithelial cell damage via inhibiting the nlrp3-asc-caspase-1-gsdmd pyroptosis pathway in dry eye disease. J Inflamm Res. (2021) 14:2955\u201362. 10.2147/JIR.S310116", "ArticleIdList": ["10.2147/JIR.S310116", "PMC8274828", "34262321"]}, {"Citation": "Zheng Q, Ren Y, Reinach PS, Xiao B, Lu H, Zhu Y, et al. . Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients. Exp Eye Res. (2015) 134:133\u201340. 10.1016/j.exer.2015.02.013", "ArticleIdList": ["10.1016/j.exer.2015.02.013", "25701684"]}, {"Citation": "Yang S, Kam WR, Liu Y, Ding J, Li Y, Sullivan DA. Comparative influence of differentiation and proliferation on gene expression in human meibomian gland epithelial cells. Exp Eye Res. (2021) 205:108452. 10.1016/j.exer.2021.108452", "ArticleIdList": ["10.1016/j.exer.2021.108452", "33493473"]}, {"Citation": "Ellenbroek G, de Haan JJ, van Klarenbosch BR, Brans MAD, van de Weg SM, Smeets MB, et al. . Leukocyte-Associated Immunoglobulin-like Receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice. Sci Rep. (2017) 7:18039. 10.1038/s41598-017-13678-5", "ArticleIdList": ["10.1038/s41598-017-13678-5", "PMC5740066", "29269840"]}, {"Citation": "Rotzer V, Melega F, Garreis F, Paulsen F, Waschke J. E-Cadherin Is Important for Meibomian Gland Function as Revealed by a New Human ex Vivo Slice Culture Model. Am J Pathol. (2019) 189:1559\u201368. 10.1016/j.ajpath.2019.04.015", "ArticleIdList": ["10.1016/j.ajpath.2019.04.015", "31121132"]}, {"Citation": "Yoon KC, Ahn KY, Choi W, Li Z, Choi JS, Lee SH, et al. . Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress. Invest Ophthalmol Vis Sci. (2011) 52:7267\u201373. 10.1167/iovs.11-7231", "ArticleIdList": ["10.1167/iovs.11-7231", "21849424"]}, {"Citation": "Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. (2015) 112:71\u201381. 10.3238/arztebl.2015.0071", "ArticleIdList": ["10.3238/arztebl.2015.0071", "PMC4335585", "25686388"]}, {"Citation": "Mashaghi A, Hong JX, Chauhan SK, Dana R. Ageing and ocular surface immunity. Brit J Ophthalmol. (2017) 101:1\u20135. 10.1136/bjophthalmol-2015-307848", "ArticleIdList": ["10.1136/bjophthalmol-2015-307848", "PMC5583682", "27378485"]}, {"Citation": "Golden MI, Meyer JJ, Patel BC. Dry eye syndrome. StatPearls Treasure Island (FL). (2021).", "ArticleIdList": ["29262012"]}, {"Citation": "Mittal R, Patel S, Galor A. Alternative therapies for dry eye disease. Curr Opin Ophthalmol. (2021) 32:348\u201361. 10.1097/ICU.0000000000000768", "ArticleIdList": ["10.1097/ICU.0000000000000768", "PMC8169641", "34010229"]}, {"Citation": "Kim M, Lee Y, Mehra D, Sabater AL, Galor A. Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol. (2021) 6:e000697. 10.1136/bmjophth-2020-000697", "ArticleIdList": ["10.1136/bmjophth-2020-000697", "PMC8039249", "33907713"]}, {"Citation": "Reichstein D. Current treatments and preventive strategies for radiation retinopathy. Curr Opin Ophthalmol. (2015) 26:157\u201366. 10.1097/ICU.0000000000000141", "ArticleIdList": ["10.1097/ICU.0000000000000141", "25730680"]}, {"Citation": "Jackson AJ, Wolsley CJ. Rigid gas permeable contact lenses: out in the cold. Cont Lens Anterior Eye. (2009) 32:204\u20136. 10.1016/j.clae.2009.06.006", "ArticleIdList": ["10.1016/j.clae.2009.06.006", "19596604"]}, {"Citation": "Wu X, Ma Y, Chen X, He S, Lin X, Yu X, et al. . Efficacy of bandage contact lens for the management of dry eye disease after cataract surgery. Int Ophthalmol. (2021) 41:1403\u201313. 10.1007/s10792-021-01692-6", "ArticleIdList": ["10.1007/s10792-021-01692-6", "PMC8035101", "33507461"]}, {"Citation": "Nichols JJ, Bickle KM, Zink RC, Schiewe MD, Haque RM, Nichols KK. Safety and efficacy of topical azithromycin ophthalmic solution 10% in the treatment of contact lens-related dry eye. Eye Contact Lens. (2012) 38:73\u20139. 10.1097/ICL.0b013e31823ff229", "ArticleIdList": ["10.1097/ICL.0b013e31823ff229", "22157392"]}, {"Citation": "Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. (2013) 32:44\u201353. 10.1097/ICO.0b013e318254205f", "ArticleIdList": ["10.1097/ICO.0b013e318254205f", "PMC4138220", "22668581"]}, {"Citation": "Xue AL, Downie LE, Ormonde SE, Craig JP. A comparison of the self-reported dry eye practices of New Zealand optometrists and ophthalmologists. Ophthalmic Physiol Opt. (2017) 37:191\u2013201. 10.1111/opo.12349", "ArticleIdList": ["10.1111/opo.12349", "28211183"]}, {"Citation": "Doughty MJ. On the prescribing of oral doxycycline or minocycline by UK optometrists as part of management of chronic Meibomian Gland Dysfunction (MGD). Cont Lens Anterior Eye. (2016) 39:2\u20138. 10.1016/j.clae.2015.08.002", "ArticleIdList": ["10.1016/j.clae.2015.08.002", "26347083"]}, {"Citation": "Hagen KB, Bedi R, Blackie CA, Christenson-Akagi KJ. Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clin Ophthalmol. (2018) 12:161\u20138. 10.2147/OPTH.S150433", "ArticleIdList": ["10.2147/OPTH.S150433", "PMC5775735", "29398903"]}, {"Citation": "Aronowicz JD, Shine WE, Oral D, Vargas JM, McCulley JP. Short term oral minocycline treatment of meibomianitis. Br J Ophthalmol. (2006) 90:856\u201360. 10.1136/bjo.2006.091579", "ArticleIdList": ["10.1136/bjo.2006.091579", "PMC1857131", "16613920"]}, {"Citation": "Schechter BA. Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis. Expert Opin Drug Metab Toxicol. (2008) 4:507\u201311. 10.1517/17425255.4.4.507", "ArticleIdList": ["10.1517/17425255.4.4.507", "18433352"]}, {"Citation": "Torres-Luna C, Hu N, Tammareddy T, Domszy R, Yang J, Wang NS, et al. . Extended delivery of non-steroidal anti-inflammatory drugs through contact lenses loaded with Vitamin E and cationic surfactants. Cont Lens Anterior Eye. (2019) 42:546\u201352. 10.1016/j.clae.2019.04.011", "ArticleIdList": ["10.1016/j.clae.2019.04.011", "31085116"]}, {"Citation": "Liu X, Wang S, Kao AA, Long Q. The effect of topical pranoprofen 01% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes. Cornea. (2012) 31:1235\u20139. 10.1097/ICO.0b013e31824988e5", "ArticleIdList": ["10.1097/ICO.0b013e31824988e5", "22677643"]}, {"Citation": "Chen J, Dong F, Chen W, Sun X, Deng Y, Hong J, et al. . Clinical efficacy of 01% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial. Chin Med J (Engl). (2014) 127:2407\u201312.", "ArticleIdList": ["24985574"]}, {"Citation": "Kilic S, Kulualp K. Efficacy of several therapeutic agents in a murine model of dry eye syndrome. Comp Med. (2016) 66:112\u20138.", "ArticleIdList": ["PMC4825960", "27053565"]}, {"Citation": "Kato K, Miyake K, Kondo N, Asano S, Takeda J, Takahashi A, et al. . Conjunctival goblet cell density following cataract surgery with diclofenac versus diclofenac and rebamipide: a randomized trial. Am J Ophthalmol. (2017) 181:26\u201336. 10.1016/j.ajo.2017.06.016", "ArticleIdList": ["10.1016/j.ajo.2017.06.016", "28669778"]}, {"Citation": "Honkanen RA, Huang L, Xie G, Rigas B. Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease. Transl Res. (2018) 198:58\u201372. 10.1016/j.trsl.2018.04.002", "ArticleIdList": ["10.1016/j.trsl.2018.04.002", "29702077"]}, {"Citation": "Huang W, Wen Z, Saglam MS, Huang L, Honkanen RA, Rigas B. Phospho-Sulindac (OXT-328) inhibits dry eye disease in rabbits: a dose-, formulation- and structure-dependent effect. J Ocul Pharmacol Ther. (2021) 37:321\u201330. 10.1089/jop.2019.0025", "ArticleIdList": ["10.1089/jop.2019.0025", "34152861"]}, {"Citation": "Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. (2003) 136:593\u2013602. 10.1016/S0002-9394(03)00326-X", "ArticleIdList": ["10.1016/S0002-9394(03)00326-X", "14516798"]}, {"Citation": "Zhu L, Zhang C, Chuck RS. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. Mol Vis. (2012) 8:1803\u201312.", "ArticleIdList": ["PMC3398490", "22815633"]}, {"Citation": "Kawahara A, Utsunomiya T, Kato Y, Takayanagi Y. Comparison of effect of nepafenac and diclofenac ophthalmic solutions on cornea, tear film, and ocular surface after cataract surgery: the results of a randomized trial. Clin Ophthalmol. (2016) 10:385\u201391. 10.2147/OPTH.S101836", "ArticleIdList": ["10.2147/OPTH.S101836", "PMC4786065", "27019091"]}, {"Citation": "Yanai K, Huang J, Kadonosono K, Uchio E. Corneal sensitivity after topical bromfenac sodium eye-drop instillation. Clin Ophthalmol. (2013) 7:741\u20134. 10.2147/OPTH.S41801", "ArticleIdList": ["10.2147/OPTH.S41801", "PMC3632625", "23626458"]}, {"Citation": "Fujishima H, Fuseya M, Ogata M, Murat D. Efficacy of bromfenac sodium ophthalmic solution for treatment of dry eye disease. Asia Pac J Ophthalmol (Phila). (2015) 4:9\u201313. 10.1097/APO.0000000000000032", "ArticleIdList": ["10.1097/APO.0000000000000032", "26068607"]}, {"Citation": "Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. (2012) 154:63\u201371. 10.1016/j.ajo.2012.01.034", "ArticleIdList": ["10.1016/j.ajo.2012.01.034", "PMC3378826", "22541929"]}, {"Citation": "Lee JH, Min K, Kim SK, Kim EK, Kim TI. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone. Yonsei Med J. (2014) 55:203\u20138. 10.3349/ymj.2014.55.1.203", "ArticleIdList": ["10.3349/ymj.2014.55.1.203", "PMC3874929", "24339308"]}, {"Citation": "Kumari S, Dandamudi M, Rani S, Behaeghel E, Behl G, Kent D, et al. . Dexamethasone-loaded nanostructured lipid carriers for the treatment of dry eye disease. Pharmaceutics. (2021) 13. 10.3390/pharmaceutics13060905", "ArticleIdList": ["10.3390/pharmaceutics13060905", "PMC8234689", "34207223"]}, {"Citation": "Pinto-Fraga J, Enriquez-de-Salamanca A, Calonge M, Gonzalez-Garcia MJ, Lopez-Miguel A, Lopez-de la Rosa A, et al. . Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial. Ocul Surf. (2018) 16:368\u201376. 10.1016/j.jtos.2018.05.001", "ArticleIdList": ["10.1016/j.jtos.2018.05.001", "29772277"]}, {"Citation": "Nattinen J, Jylha A, Aapola U, Enriquez-de-Salamanca A, Pinto-Fraga J, Lopez-Miguel A, et al. . Topical fluorometholone treatment and desiccating stress change inflammatory protein expression in tears. Ocul Surf. (2018) 16:84\u201392. 10.1016/j.jtos.2017.09.003", "ArticleIdList": ["10.1016/j.jtos.2017.09.003", "28918083"]}, {"Citation": "Taniguchi J, Sharma A. Fluorometholone modulates gene expression of ocular surface mucins. Acta Ophthalmol. (2019) 97:e1082\u2013e8. 10.1111/aos.14113", "ArticleIdList": ["10.1111/aos.14113", "30963711"]}, {"Citation": "Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, Solomon KD, et al. . Effect of loteprednol etabonate 05% on initiation of dry eye treatment with topical cyclosporine 005%. Eye Contact Lens. (2014) 40:289\u201396. 10.1097/ICL.0000000000000049", "ArticleIdList": ["10.1097/ICL.0000000000000049", "25083776"]}, {"Citation": "Chen W, Shi XL, He XH, Mao YH, Li C, Dong N. Loteprednol combined with sodium hyaluronate in the treatment of dry eye disease and its effect on TNF-alpha and CXCL10 in tears. J Biol Regul Homeost Agents. (2020) 34:1825\u20139.", "ArticleIdList": ["33103412"]}, {"Citation": "Burade V, Zalawadia R, Patel A, Ogundele A. Preclinical efficacy comparison of cyclosporine ophthalmic solution 009% vs cyclosporine ophthalmic emulsion 005% vs ciclosporin ophthalmic emulsion 01% in a NOD mouse model of dry eye disease. Clin Ophthalmol. (2020) 14:2747\u201355. 10.2147/OPTH.S259331", "ArticleIdList": ["10.2147/OPTH.S259331", "PMC7518773", "33061257"]}, {"Citation": "Cubuk MO, Ucgul AY, Ozgur A, Ozulken K, Yuksel E. Topical cyclosporine a (005%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome. Int Ophthalmol. (2021) 41:1479\u201385. 10.1007/s10792-021-01708-1", "ArticleIdList": ["10.1007/s10792-021-01708-1", "33484384"]}, {"Citation": "Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, Hoshino-Ruiz DR, Albers MB, Santo RM, et al. . Treatment of Sjogren's syndrome dry eye using 003% tacrolimus eye drop: Prospective double-blind randomized study. Cont Lens Anterior Eye. (2015) 38:373\u20138. 10.1016/j.clae.2015.04.004", "ArticleIdList": ["10.1016/j.clae.2015.04.004", "25956572"]}, {"Citation": "Moawad P, Shamma R, Hassanein D, Ragab G, El Zawahry O. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome. Eur J Ophthalmol. (2021) 1120672121992680. 10.1177/1120672121992680", "ArticleIdList": ["10.1177/1120672121992680", "33530719"]}, {"Citation": "Alam J, de Souza RG, Yu Z, Stern ME, de Paiva CS, Pflugfelder SC. Calcineurin inhibitor voclosporin preserves corneal barrier and conjunctival goblet cells in experimental dry eye. J Ocul Pharmacol Ther. (2020) 36:679\u201385. 10.1089/jop.2020.0005", "ArticleIdList": ["10.1089/jop.2020.0005", "PMC7703159", "32721249"]}, {"Citation": "Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Curr Opin Rheumatol. (2020) 32:609\u201316. 10.1097/BOR.0000000000000754", "ArticleIdList": ["10.1097/BOR.0000000000000754", "33002950"]}, {"Citation": "Gonzalez AL. Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort. Clin Ophthalmol. (2018) 12:2079\u201385. 10.2147/OPTH.S184776", "ArticleIdList": ["10.2147/OPTH.S184776", "PMC6200428", "30425447"]}, {"Citation": "Tong AY, Passi SF, Gupta PK. Clinical outcomes of lifitegrast 5% ophthalmic solution in the treatment of dry eye disease. Eye Contact Lens. (2020) 46 Suppl 1:S20\u2013S4. 10.1097/ICL.0000000000000601", "ArticleIdList": ["10.1097/ICL.0000000000000601", "30985492"]}, {"Citation": "Sosne G, Kim C, Kleinman HK. Thymosin beta4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye. Expert Opin Biol Ther. (2015) 15 Suppl 1:S155\u201361. 10.1517/14712598.2015.1019858", "ArticleIdList": ["10.1517/14712598.2015.1019858", "26096547"]}, {"Citation": "Jin R, Li Y, Li L, Kim DH, Yang CD, Son HS, et al. . Anti-inflammatory effects of glycine thymosin beta4 eye drops in experimental dry eye. Biomed Rep. (2020) 12:319\u201325. 10.3892/br.2020.1296", "ArticleIdList": ["10.3892/br.2020.1296", "PMC7201140", "32382416"]}, {"Citation": "Wolffsohn JS, Trave Huarte S, Jones L, Craig JP, Wang MTM. Ambassadors T. clinical practice patterns in the management of dry eye disease: A TFOS international survey. Ocul Surf. (2021) 21:78\u201386. 10.1016/j.jtos.2021.04.011", "ArticleIdList": ["10.1016/j.jtos.2021.04.011", "33964411"]}, {"Citation": "Zhang Z, Yang WZ, Zhu ZZ, Hu QQ, Chen YF, He H, et al. . Therapeutic effects of topical doxycycline in a benzalkonium chloride-induced mouse dry eye model. Invest Ophth Vis Sci. (2014) 55:2963\u201374. 10.1167/iovs.13-13577", "ArticleIdList": ["10.1167/iovs.13-13577", "24722696"]}, {"Citation": "Coursey TG, de Paiva CS. Managing Sjogren's Syndrome and non-Sjogren Syndrome dry eye with anti-inflammatory therapy. Clinical Ophthalmology. (2014) 8:1447\u201358. 10.2147/OPTH.S35685", "ArticleIdList": ["10.2147/OPTH.S35685", "PMC4128848", "25120351"]}, {"Citation": "Singer DD, Kennedy J, Wittpenn JR. Topical NSAIDs effect on corneal sensitivity. Cornea. (2015) 34:541\u20133. 10.1097/ICO.0000000000000309", "ArticleIdList": ["10.1097/ICO.0000000000000309", "25826326"]}, {"Citation": "Clayton JA. Dry eye. N Engl J Med. (2018) 379:e19. 10.1056/NEJMc1808906", "ArticleIdList": ["10.1056/NEJMc1808906", "30211496"]}, {"Citation": "Hayasaka Y, Hayasaka S, Zhang XY, Nagaki Y. Effects of topical corticosteroids and nonsteroidal anti-inflammatory drugs on prostaglandin e2-induced aqueous flare elevation in pigmented rabbits. Ophthalmic Res. (2003) 35:341\u20134. 10.1159/000074074", "ArticleIdList": ["10.1159/000074074", "14688425"]}, {"Citation": "Walters TR, Goldberg DF, Peace JH, Gow JA. Bromfenac Ophthalmic Solution 0.07% Once Daily Study G. Bromfenac ophthalmic solution 007% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology. (2014) 121:25\u201333. 10.1016/j.ophtha.2013.07.006", "ArticleIdList": ["10.1016/j.ophtha.2013.07.006", "24021896"]}, {"Citation": "Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. . TFOS DEWS II Management and Therapy Report. Ocular Surface. (2017) 15:575\u2013628. 10.1016/j.jtos.2017.05.006", "ArticleIdList": ["10.1016/j.jtos.2017.05.006", "28736343"]}, {"Citation": "Pinto-Fraga J, Lopez-Miguel A, Gonzalez-Garcia MJ, Fernandez I, Lopez-de-la-Rosa A, Enriquez-de-Salamanca A, et al. . Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial. Ophthalmology. (2016) 123:141\u201353. 10.1016/j.ophtha.2015.09.029", "ArticleIdList": ["10.1016/j.ophtha.2015.09.029", "26520171"]}, {"Citation": "Beckman K, Katz J, Majmudar P, Rostov A. Loteprednol etabonate for the treatment of dry eye disease. J Ocul Pharmacol Ther. (2020) 36:497\u2013511. 10.1089/jop.2020.0014", "ArticleIdList": ["10.1089/jop.2020.0014", "PMC7482125", "32391735"]}, {"Citation": "Lotepredno l0.25% (Eysuvis) for dry eye disease . Med Lett Drugs Ther. (2021) 63:75\u20137.", "ArticleIdList": ["33976092"]}, {"Citation": "Korenfeld M, Nichols KK, Goldberg D, Evans D, Sall K, Foulks G, et al. . Safety of KPI-121 ophthalmic suspension 025% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies. Cornea. (2021) 40:564\u201370. 10.1097/ICO.0000000000002452", "ArticleIdList": ["10.1097/ICO.0000000000002452", "32826644"]}, {"Citation": "Zhang XY, Zhao L, Deng SJ, Sun XG, Wang NL. Dry eye syndrome in patients with diabetes mellitus: prevalence, etiology, and clinical characteristics. J Ophthalmol. (2016) 2016. 10.1155/2016/8201053", "ArticleIdList": ["10.1155/2016/8201053", "PMC4861815", "27213053"]}, {"Citation": "Fajnkuchen F, Barritault D, Giocanti-Auregan A. Evaluation of a new matrix regenerating agent in patients with Sjogren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases. Medicine (Baltimore). (2018) 97:e9935. 10.1097/MD.0000000000009935", "ArticleIdList": ["10.1097/MD.0000000000009935", "PMC5882434", "29517701"]}, {"Citation": "Lin BW, Chen MZ, Fan SX, Chuck RS, Zhou SY. Effect of 0025% FK-506 eyedrops on botulinum toxin B-induced mouse dry eye. Invest Ophthalmol Vis Sci. (2014) 56:45\u201353. 10.1167/iovs.13-12925", "ArticleIdList": ["10.1167/iovs.13-12925", "25491293"]}, {"Citation": "Mu J, Zeng D, Fan J, Liu M, Yu S, Ding W, et al. . Associations between air pollution exposure and daily pediatric outpatient visits for dry eye disease: a time-series study in shenzhen, China. Int J Public Health. (2021) 66:1604235. 10.3389/ijph.2021.1604235", "ArticleIdList": ["10.3389/ijph.2021.1604235", "PMC8415162", "34483811"]}, {"Citation": "Pflugfelder SC, Stern M, Zhang S, Shojaei A. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. (2017) 33:5\u201312. 10.1089/jop.2016.0105", "ArticleIdList": ["10.1089/jop.2016.0105", "PMC5240001", "27906544"]}, {"Citation": "Chan CC, Prokopich CL. Lifitegrast Ophthalmic Solution 50% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program. J Pharm Pharm Sci. (2019) 22:49\u201356. 10.18433/jpps29895", "ArticleIdList": ["10.18433/jpps29895", "30636670"]}, {"Citation": "Hovanesian JA, Nichols KK, Jackson M, Katz J, Chan A, Glassberg MB, et al. . Real-world experience with lifitegrast ophthalmic solution (Xiidra((R))) in the US and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. (2021) 15:1041\u201354. 10.2147/OPTH.S296510", "ArticleIdList": ["10.2147/OPTH.S296510", "PMC7953885", "33727786"]}, {"Citation": "Guimaraes de Souza R, Yu Z, Stern ME, Pflugfelder SC, de Paiva CS. Suppression of Th1-mediated keratoconjunctivitis sicca by lifitegrast. J Ocul Pharmacol Ther. (2018) 34:543\u20139. 10.1089/jop.2018.0047", "ArticleIdList": ["10.1089/jop.2018.0047", "PMC6909696", "29958030"]}, {"Citation": "Sosne G, Qiu P, Ousler GW. 3rd, Dunn SP, Crockford D. Thymosin beta4: a potential novel dry eye therapy. Ann N Y Acad Sci. (2012) 1270:45\u201350. 10.1111/j.1749-6632.2012.06682.x", "ArticleIdList": ["10.1111/j.1749-6632.2012.06682.x", "23050816"]}, {"Citation": "Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. (2015) 9:877\u201384. 10.2147/OPTH.S80954", "ArticleIdList": ["10.2147/OPTH.S80954", "PMC4445951", "26056426"]}, {"Citation": "Kim CE, Kleinman HK, Sosne G, Ousler GW, Kim K, Kang S, et al. . RGN-259 (thymosin beta4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. Sci Rep. (2018) 8:10500. 10.1038/s41598-018-28861-5", "ArticleIdList": ["10.1038/s41598-018-28861-5", "PMC6043477", "30002412"]}, {"Citation": "Zhang C, Li K, Yang Z, Wang Y, Si H. The effect of the aqueous extract of bidens pilosa L. on androgen deficiency dry eye in rats. Cell Physiol Biochem. (2016) 39:266\u201377. 10.1159/000445622", "ArticleIdList": ["10.1159/000445622", "27337217"]}, {"Citation": "Qin G, Zhou Y, Peng J, Zhang Y, Peng X, Peng Q, et al. . The effect of buddleja officinalis maxim eye drops on morphology and apoptosis in lacrimal gland of experimental dry eye rabbit model. J Ophthalmol. (2019) 2019:5916243. 10.1155/2019/5916243", "ArticleIdList": ["10.1155/2019/5916243", "PMC6379849", "30867962"]}, {"Citation": "Peng QH, Yao XL, Wu QL, Tan HY, Zhang JR. Effects of extract of Buddleja officinalis eye drops on androgen receptors of lacrimal gland cells of castrated rats with dry eye. Int J Ophthalmol. (2010) 3:43\u20138. 10.3736/jcim20100308", "ArticleIdList": ["10.3736/jcim20100308", "PMC3340645", "22553515"]}, {"Citation": "Yao XL, Peng QH, Chen QL, Tang YH, Zhong Q. Effects of total flavonoid of chrysanthemum on Fas and Fasl expression in lacrimal gland cells of male castrated rabbits with dry eye. Guoji Yanke Zazhi. (2014) 14:1749\u201354. 10.3980/j.issn.1672-5123.2014.10.03", "ArticleIdList": ["10.3980/j.issn.1672-5123.2014.10.03"]}, {"Citation": "Jian S, Li-Hao C, Qian-Hong L, Jun P, Yu T, Xiao-Lei Y, et al. . Inflammatory mechanism of total flavonoids of chrysanthemum and medicated serum on castrated dry eye animal and cell models. Digital Chinese Medicine. (2020) 3:283\u201396. 10.1016/j.dcmed.2020.12.007", "ArticleIdList": ["10.1016/j.dcmed.2020.12.007"]}, {"Citation": "Lee H, Kim MY, Ji SY, Kim DH, Kim SY, Hwangbo H, et al. . The protective effect of oral application of corni fructus on the disorders of the cornea, conjunctiva, lacrimal gland and retina by topical particulate matter 2.5. Nutrients. (2021) 13:2986. 10.3390/nu13092986", "ArticleIdList": ["10.3390/nu13092986", "PMC8464674", "34578864"]}, {"Citation": "Liu Z, Jin M, Li Y, Liu J, Xiao X, Bi H, et al. . Efficacy and safety of houttuynia eye drops atomization treatment for meibomian gland dysfunction-related dry eye disease: a randomized, double-blinded, placebo-controlled clinical trial. J Clin Med. (2020) 9:4022. 10.3390/jcm9124022", "ArticleIdList": ["10.3390/jcm9124022", "PMC7763017", "33322753"]}, {"Citation": "Park B, Lee IS, Hyun SW, Jo K, Lee TG, Kim JS, et al. . The protective effect of Polygonum cuspidatum (PCE) aqueous extract in a dry eye model. Nutrients. (2018) 10:1550. 10.3390/nu10101550", "ArticleIdList": ["10.3390/nu10101550", "PMC6212923", "30347752"]}, {"Citation": "Park B, Jo K, Lee TG, Hyun SW, Kim JS, Kim CS. Polydatin inhibits NLRP3 inflammasome in dry eye disease by attenuating oxidative stress and inhibiting the NF-kappaB pathway. Nutrients. (2019) 11:2792. 10.3390/nu11112792", "ArticleIdList": ["10.3390/nu11112792", "PMC6893769", "31731792"]}, {"Citation": "Park B, Lee TG, Hyun S, Jo K, Lee IS, Jin SK, et al. . The effect of Polydatin in dry eye disease in vivo and in vitro. The FASEB J. (2019) 33. 10.1096/fasebj.2019.33.1_supplement.lb388", "ArticleIdList": ["10.1096/fasebj.2019.33.1_supplement.lb388", "PMC6893769", "31731792"]}, {"Citation": "Wang SJ, Wang XH, Dai YY, Ma MH, Rahman K, Nian H, et al. . Prunella vulgaris: a comprehensive review of chemical constituents, pharmacological effects and clinical applications. Curr Pharm Design. (2019) 25:359\u201369. 10.2174/1381612825666190313121608", "ArticleIdList": ["10.2174/1381612825666190313121608", "30864498"]}, {"Citation": "Jarvinen RL, Larmo PS, Setala NL, Yang B, Engblom JR, Viitanen MH, et al. . Effects of oral sea buckthorn oil on tear film Fatty acids in individuals with dry eye. Cornea. (2011) 30:1013\u20139. 10.1097/ICO.0b013e3182035ad9", "ArticleIdList": ["10.1097/ICO.0b013e3182035ad9", "21832964"]}, {"Citation": "Wang B, Lin L, Ni Q, Su CL. Hippophae rhamnoides Linn. for treatment of diabetes mellitus: A review. J Med Plants Res. (2011) 5:2599\u2013607."}, {"Citation": "Larmo P, Jarvinen R, Laihia J, Loyttyniemi E, Maavirta L, Yang B, et al. . Effects of a sea buckthorn oil spray emulsion on dry eye. Cont Lens Anterior Eye. (2019) 42:428\u201333. 10.1016/j.clae.2018.11.011", "ArticleIdList": ["10.1016/j.clae.2018.11.011", "30497904"]}, {"Citation": "Kim CS, Jo K, Lee IS, Kim J. Topical application of apricot kernel extract improves dry eye symptoms in a unilateral exorbital lacrimal gland excision mouse. Nutrients. (2016) 8:750. 10.3390/nu8110750", "ArticleIdList": ["10.3390/nu8110750", "PMC5133132", "27886047"]}, {"Citation": "Hyun SW, Kim J, Park B, Jo K, Lee TG, Kim JS, et al. . Apricot kernel extract and amygdalin inhibit urban particulate matter-induced keratoconjunctivitis sicca. Molecules. (2019) 24:650. 10.3390/molecules24030650", "ArticleIdList": ["10.3390/molecules24030650", "PMC6384987", "30759852"]}, {"Citation": "Kang SW, Kim KA, Lee CH, Yang SJ, Kang TK, Jung JH, et al. . A standardized extract of Rhynchosia volubilis Lour. exerts a protective effect on benzalkonium chloride-induced mouse dry eye model. J Ethnopharmacol. (2018) 215:91\u2013100. 10.1016/j.jep.2017.12.041", "ArticleIdList": ["10.1016/j.jep.2017.12.041", "29288830"]}, {"Citation": "Liu L, Lao W, Ji QS, Yang ZH, Yu GC, Zhong JX. Lycium barbarum polysaccharides protected human retinal pigment epithelial cells against oxidative stress-induced apoptosis. Int J Ophthalmol. (2015) 8:11\u20136. 10.3980/j.issn.2222-3959.2015.01.02", "ArticleIdList": ["10.3980/j.issn.2222-3959.2015.01.02", "PMC4325234", "25709900"]}, {"Citation": "Chien KJ, Horng CT, Huang YS, Hsieh YH, Wang CJ, Yang JS, et al. . Effects of Lycium barbarum (goji berry) on dry eye disease in rats. Mol Med Rep. (2018) 17:809\u201318. 10.3892/mmr.2017.7947", "ArticleIdList": ["10.3892/mmr.2017.7947", "PMC5780158", "29115477"]}, {"Citation": "Xu S, Liu S, Yan G. Lycium barbarum exerts protection against glaucoma-like injury via inhibition of MMP-9 signaling in vitro. Med Sci Monit. (2019) 25:9794\u2013800. 10.12659/MSM.919187", "ArticleIdList": ["10.12659/MSM.919187", "PMC6936211", "31860907"]}, {"Citation": "Zeng Q, Ko CH, Siu WS, Li KK, Wong CW, Han XQ, et al. . Inhibitory effect of different Dendrobium species on LPS-induced inflammation in macrophages via suppression of MAPK pathways. Chin J Nat Medicines. (2018) 16:481\u20139. 10.1016/S1875-5364(18)30083-9", "ArticleIdList": ["10.1016/S1875-5364(18)30083-9", "30080646"]}, {"Citation": "Zeng Q, Siu WS, Ko CH, Wong CW, Bik-San Lau C, Wu ZZ, et al. . Dendrobium officinale Kimura et Migo Improved Dry Eye Symptoms via Promoting Tear Production in an Experimental Dry Eye Rat Model. Pharmacogn Mag. (2020) 16:294\u2013302."}, {"Citation": "Xiao L, Ng TB, Feng YB, Yao T, Wong JH, Yao RM, et al. . Dendrobium candidum extract increases the expression of aquaporin-5 in labial glands from patients with Sjogren's syndrome. Phytomedicine. (2011) 18:194\u20138. 10.1016/j.phymed.2010.05.002", "ArticleIdList": ["10.1016/j.phymed.2010.05.002", "20655712"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "11", "Day": "17"}, {"Year": "2021", "Month": "12", "Day": "27"}, {"Year": "2022", "Month": "2", "Day": "3", "Hour": "5", "Minute": "35"}, {"Year": "2022", "Month": "2", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "4", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "1", "Day": "17"}], "PublicationStatus": "epublish", "ArticleIdList": ["35111787", "PMC8801439", "10.3389/fmed.2021.815075"]}}], "PubmedBookArticle": []}